Omaha NE 小细胞肺癌临床试验
8项针对 小细胞肺癌的研究正在 Omaha及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
招募中1 期
- Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
招募中3 期
- University of Nebraska Medical Center, Omaha
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
招募中3 期
- Oncology Hematology West PC, Omaha
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
招募中3 期
- University of Nebraska Medical Center, Omaha
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
招募中1/2 期
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
其他城市的 小细胞肺癌试验
- Houston, TX26 项研究
- Arlington, VA23 项研究
- New York City, NY22 项研究
- Boston, MA21 项研究
- Los Angeles, CA20 项研究
- Nashville, TN20 项研究
- Orlando, FL15 项研究
- Dallas, TX13 项研究
- Cleveland, OH13 项研究
- Chicago, IL13 项研究
- St. Louis, MO13 项研究
- Detroit, MI12 项研究
Omaha的其他研究
- 前列腺癌27 项研究
- 非小细胞肺癌24 项研究
- 乳腺癌22 项研究
- 癌症（所有类型）18 项研究
- 结直肠癌18 项研究
- 多发性骨髓瘤16 项研究
- 卵巢癌14 项研究
- 非霍奇金淋巴瘤14 项研究
- 胰腺癌14 项研究
- 转移性癌症13 项研究
- 头颈鳞状细胞癌13 项研究
- 心力衰竭13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。